APO Research
Talk to an analyst

APO RESEARCH · REPORT

Hepatitis A Vaccine

Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.

Two types of HAV vaccines are currently available internationally:

1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).

2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and sporadically in the private sector in India.

Selected research

Market Outlook & Growth Opportunities

Global Hepatitis A Vaccine Market Outlook and Growth Opportunities 2026

26 December 2025192 pages

Choose your research edition.

Industry ResearchHepatitis A Vaccine Industry Research Report 2026121 pages · $2,950 USDIndustry Growth & TrendsGlobal Hepatitis A Vaccine Industry Growth and Trends Forecast to 2032106 pages · $3,450 USDMarket StructureGlobal Hepatitis A Vaccine Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Hepatitis A Vaccine Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal Hepatitis A Vaccine Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

Hepatitis A vaccine is a vaccine which is against the hepatitis A virus. The Hepatitis A vaccine is available for long-term prevention of HAV infection, Minimum age for HAV vaccination is 1 year.

Two types of HAV vaccines are currently available internationally:

1. Formaldehyde-inactivated vaccines: Inactivated HAV vaccines are used in most countries. Monovalent inactivated HAV vaccines are available in paediatric dose (0.5 ml) for children aged 1 year to 15 years, and in adult dose (1 ml).

Read the full market overview

2. Live attenuated vaccines (based on H2 or LA-1 HAV strains): These vaccines are manufactured and used mainly in China and sporadically in the private sector in India.

Global Hepatitis A Vaccine key players include GSK, Merck, Sanofi, etc. Global top three manufacturers hold a share over 85%.

Europe is the largest market, with a share over 30%, followed by North America and China, both have a share about 45 percent.

In terms of product, Inactivated Vaccine is the largest segment, with a share about 70%. And in terms of application, the largest application is Government Institution, followed by Private Sector, etc.

This report provides an overview of the global Hepatitis A Vaccine market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Hepatitis A Vaccine and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Hepatitis A Vaccine sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Hepatitis A Vaccine market size, projected growth trends, production technologies, key applications, and end-use industries.

Hepatitis A Vaccine Segment by Company

GSK

Merck

Sanofi

Sinovac

Zhejiang Pukang

Changchun Institute of Biological

KM Biologics

IMBCA

ChangSheng

Convac

Hepatitis A Vaccine Segment by Type

Inactivated Vaccine

Live Attenuated Vaccine

Hepatitis A Vaccine Segment by Application

Government Institution

Private Sector

Other

Hepatitis A Vaccine Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Hepatitis A Vaccine status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Hepatitis A Vaccine market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Hepatitis A Vaccine significant trends, drivers, influence factors in global and regions.

6. To analyze Hepatitis A Vaccine competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Hepatitis A Vaccine market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Hepatitis A Vaccine and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Hepatitis A Vaccine.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Hepatitis A Vaccine market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Hepatitis A Vaccine industry.

Chapter 3: Detailed analysis of Hepatitis A Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Hepatitis A Vaccine in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Hepatitis A Vaccine in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Hepatitis A Vaccine Industry Trends Table 2. Hepatitis A Vaccine Industry Drivers Table 3. Hepatitis A Vaccine Industry Opportunities and Challenges Table 4. Hepatitis A Vaccine Industry Restraints Table 5. Global Hepatitis A Vaccine Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Hepatitis A Vaccine Revenue Share by Company (2021-2026) Table 7. Global Hepatitis A Vaccine Sales Volume by Company (K Unit) & (2021-2026) Table 8. Global Hepatitis A Vaccine Sales Volume Share by Company (2021-2026) Table 9. Global Hepatitis A Vaccine Average Price (USD/Unit) of Company (2021-2026) Table 10. Global Hepatitis A Vaccine Company Ranking, (2024-2026) & (USD Million) Table 11. Global Hepatitis A Vaccine Key Company Manufacturing Base & Headquarters Table 12. Global Hepatitis A Vaccine Company, Product Type & Application Table 13. Global Hepatitis A Vaccine Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Hepatitis A Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Inactivated Vaccine Table 18. Significant Companies of Live Attenuated Vaccine Table 19. Global Hepatitis A Vaccine Sales Volume by Type 2021 VS 2025 VS 2032 (K Unit) Table 20. Global Hepatitis A Vaccine Sales Volume by Type (2021-2026) & (K Unit) Table 21. Global Hepatitis A Vaccine Sales Volume by Type (2027-2032) & (K Unit) Table 22. Global Hepatitis A Vaccine Sales Volume Share by Type (2021-2026) Table 23. Global Hepatitis A Vaccine Sales Volume Share by Type (2027-2032) Table 24. Global Hepatitis A Vaccine Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Hepatitis A Vaccine Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Hepatitis A Vaccine Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Hepatitis A Vaccine Sales Value Share by Type (2021-2026) Table 28. Global Hepatitis A Vaccine Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Government Institution Table 30. Significant Companies of Private Sector Table 31. Significant Companies of Other Table 32. Global Hepatitis A Vaccine Sales Volume by Application 2021 VS 2025 VS 2032 (K Unit) Table 33. Global Hepatitis A Vaccine Sales Volume by Application (2021-2026) & (K Unit) Table 34. Global Hepatitis A Vaccine Sales Volume by Application (2027-2032) & (K Unit) Table 35. Global Hepatitis A Vaccine Sales Volume Share by Application (2021-2026) Table 36. Global Hepatitis A Vaccine Sales Volume Share by Application (2027-2032) Table 37. Global Hepatitis A Vaccine Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global Hepatitis A Vaccine Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global Hepatitis A Vaccine Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global Hepatitis A Vaccine Sales Value Share by Application (2021-2026) Table 41. Global Hepatitis A Vaccine Sales Value Share by Application (2027-2032) Table 42. Global Hepatitis A Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Unit) Table 43. Global Hepatitis A Vaccine Sales by Region (2021-2026) & (K Unit) Table 44. Global Hepatitis A Vaccine Sales Market Share by Region (2021-2026) Table 45. Global Hepatitis A Vaccine Sales by Region (2027-2032) & (K Unit) Table 46. Global Hepatitis A Vaccine Sales Market Share by Region (2027-2032) Table 47. Global Hepatitis A Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global Hepatitis A Vaccine Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global Hepatitis A Vaccine Sales Value Share by Region (2021-2026) Table 50. Global Hepatitis A Vaccine Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global Hepatitis A Vaccine Sales Value Share by Region (2027-2032) Table 52. Global Hepatitis A Vaccine Market Average Price (USD/Unit) by Region (2021-2026) Table 53. Global Hepatitis A Vaccine Market Average Price (USD/Unit) by Region (2027-2032) Table 54. Global Hepatitis A Vaccine Sales by Country: 2021 VS 2025 VS 2032 (K Unit) Table 55. Global Hepatitis A Vaccine Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global Hepatitis A Vaccine Sales by Country (2021-2026) & (K Unit) Table 57. Global Hepatitis A Vaccine Sales Market Share by Country (2021-2026) Table 58. Global Hepatitis A Vaccine Sales by Country (2027-2032) & (K Unit) Table 59. Global Hepatitis A Vaccine Sales Market Share by Country (2027-2032) Table 60. Global Hepatitis A Vaccine Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global Hepatitis A Vaccine Sales Value Market Share by Country (2021-2026) Table 62. Global Hepatitis A Vaccine Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global Hepatitis A Vaccine Sales Value Market Share by Country (2027-2032) Table 64. GSK Company Information Table 65. GSK Business Overview Table 66. GSK Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 67. GSK Hepatitis A Vaccine Product Portfolio Table 68. GSK Recent Development Table 69. Merck Company Information Table 70. Merck Business Overview Table 71. Merck Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 72. Merck Hepatitis A Vaccine Product Portfolio Table 73. Merck Recent Development Table 74. Sanofi Company Information Table 75. Sanofi Business Overview Table 76. Sanofi Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 77. Sanofi Hepatitis A Vaccine Product Portfolio Table 78. Sanofi Recent Development Table 79. Sinovac Company Information Table 80. Sinovac Business Overview Table 81. Sinovac Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 82. Sinovac Hepatitis A Vaccine Product Portfolio Table 83. Sinovac Recent Development Table 84. Zhejiang Pukang Company Information Table 85. Zhejiang Pukang Business Overview Table 86. Zhejiang Pukang Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 87. Zhejiang Pukang Hepatitis A Vaccine Product Portfolio Table 88. Zhejiang Pukang Recent Development Table 89. Changchun Institute of Biological Company Information Table 90. Changchun Institute of Biological Business Overview Table 91. Changchun Institute of Biological Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 92. Changchun Institute of Biological Hepatitis A Vaccine Product Portfolio Table 93. Changchun Institute of Biological Recent Development Table 94. KM Biologics Company Information Table 95. KM Biologics Business Overview Table 96. KM Biologics Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 97. KM Biologics Hepatitis A Vaccine Product Portfolio Table 98. KM Biologics Recent Development Table 99. IMBCA Company Information Table 100. IMBCA Business Overview Table 101. IMBCA Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 102. IMBCA Hepatitis A Vaccine Product Portfolio Table 103. IMBCA Recent Development Table 104. ChangSheng Company Information Table 105. ChangSheng Business Overview Table 106. ChangSheng Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 107. ChangSheng Hepatitis A Vaccine Product Portfolio Table 108. ChangSheng Recent Development Table 109. Convac Company Information Table 110. Convac Business Overview Table 111. Convac Hepatitis A Vaccine Sales (K Unit), Value (US$ Million), Price (USD/Unit) and Gross Margin (2021-2026) Table 112. Convac Hepatitis A Vaccine Product Portfolio Table 113. Convac Recent Development Table 114. Key Raw Materials Table 115. Raw Materials Key Suppliers Table 116. Hepatitis A Vaccine Distributors List Table 117. Hepatitis A Vaccine Customers List Table 118. Research Programs/Design for This Report Table 119. Authors List of This Report Table 120. Secondary Sources Table 121. Primary Sources List of Figures Figure 1. Hepatitis A Vaccine Product Image Figure 2. Global Hepatitis A Vaccine Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Hepatitis A Vaccine Sales Value (2021-2032) & (US$ Million) Figure 4. Global Hepatitis A Vaccine Sales (2021-2032) & (K Unit) Figure 5. Global Hepatitis A Vaccine Sales Average Price (USD/Unit) & (2021-2032) Figure 6. Global Hepatitis A Vaccine Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Inactivated Vaccine Image Figure 10. Live Attenuated Vaccine Image Figure 11. Global Hepatitis A Vaccine Sales Volume by Type (2021 VS 2025 VS 2032) & (K Unit) Figure 12. Global Hepatitis A Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Hepatitis A Vaccine Sales Volume Share by Type (2021-2032) Figure 14. Global Hepatitis A Vaccine Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Hepatitis A Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Hepatitis A Vaccine Sales Value Share by Type (2021-2032) Figure 17. Government Institution Image Figure 18. Private Sector Image Figure 19. Other Image Figure 20. Global Hepatitis A Vaccine Sales Volume by Application (2021 VS 2025 VS 2032) & (K Unit) Figure 21. Global Hepatitis A Vaccine Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global Hepatitis A Vaccine Sales Volume Share by Application (2021-2032) Figure 23. Global Hepatitis A Vaccine Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global Hepatitis A Vaccine Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global Hepatitis A Vaccine Sales Value Share by Application (2021-2032) Figure 26. Global Hepatitis A Vaccine Sales by Region: 2021 VS 2025 VS 2032 (K Unit) Figure 27. Global Hepatitis A Vaccine Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global Hepatitis A Vaccine Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global Hepatitis A Vaccine Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America Hepatitis A Vaccine Sales Value (2021-2032) & (US$ Million) Figure 31. North America Hepatitis A Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe Hepatitis A Vaccine Sales Value (2021-2032) & (US$ Million) Figure 33. Europe Hepatitis A Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific Hepatitis A Vaccine Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific Hepatitis A Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America Hepatitis A Vaccine Sales Value (2021-2032) & (US$ Million) Figure 37. South America Hepatitis A Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa Hepatitis A Vaccine Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa Hepatitis A Vaccine Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt Hepatitis A Vaccine Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. Hepatitis A Vaccine Value Chain Figure 125. Manufacturing Cost Structure Figure 126. Hepatitis A Vaccine Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Inactivated Vaccine
  • Live Attenuated Vaccine
Applications
  • Government Institution
  • Private Sector
  • Other
Companies covered
  • GSK
  • Merck
  • Sanofi
  • Sinovac
  • Zhejiang Pukang
  • Changchun Institute of Biological
  • KM Biologics
  • IMBCA
  • ChangSheng
  • Convac

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Hepatitis A Vaccine Sales Value (2021-2032)
  4. 1.2.2 Global Hepatitis A Vaccine Sales Volume (2021-2032)
  5. 1.2.3 Global Hepatitis A Vaccine Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Hepatitis A Vaccine Market Dynamics
  1. 2.1 Hepatitis A Vaccine Industry Trends
  2. 2.2 Hepatitis A Vaccine Industry Drivers
  3. 2.3 Hepatitis A Vaccine Industry Opportunities and Challenges
  4. 2.4 Hepatitis A Vaccine Industry Restraints
3 Hepatitis A Vaccine Market by Company
  1. 3.1 Global Hepatitis A Vaccine Company Revenue Ranking in 2025
  2. 3.2 Global Hepatitis A Vaccine Revenue by Company (2021-2026)
  3. 3.3 Global Hepatitis A Vaccine Sales Volume by Company (2021-2026)
  4. 3.4 Global Hepatitis A Vaccine Average Price by Company (2021-2026)
  5. 3.5 Global Hepatitis A Vaccine Company Ranking (2024-2026)
  6. 3.6 Global Hepatitis A Vaccine Company Manufacturing Base and Headquarters
  7. 3.7 Global Hepatitis A Vaccine Company Product Type and Application
  8. 3.8 Global Hepatitis A Vaccine Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Hepatitis A Vaccine Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Hepatitis A Vaccine Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Hepatitis A Vaccine Market by Type
  1. 4.1 Hepatitis A Vaccine Type Introduction
  2. 4.1.1 Inactivated Vaccine
  3. 4.1.2 Live Attenuated Vaccine
  4. 4.2 Global Hepatitis A Vaccine Sales Volume by Type
  5. 4.2.1 Global Hepatitis A Vaccine Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Hepatitis A Vaccine Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Hepatitis A Vaccine Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Hepatitis A Vaccine Sales Value by Type
  9. 4.3.1 Global Hepatitis A Vaccine Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Hepatitis A Vaccine Sales Value by Type (2021-2032)
  11. 4.3.3 Global Hepatitis A Vaccine Sales Value Share by Type (2021-2032)
5 Hepatitis A Vaccine Market by Application
  1. 5.1 Hepatitis A Vaccine Application Introduction
  2. 5.1.1 Government Institution
  3. 5.1.2 Private Sector
  4. 5.1.3 Other
  5. 5.2 Global Hepatitis A Vaccine Sales Volume by Application
  6. 5.2.1 Global Hepatitis A Vaccine Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Hepatitis A Vaccine Sales Volume by Application (2021-2032)
  8. 5.2.3 Global Hepatitis A Vaccine Sales Volume Share by Application (2021-2032)
  9. 5.3 Global Hepatitis A Vaccine Sales Value by Application
  10. 5.3.1 Global Hepatitis A Vaccine Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Hepatitis A Vaccine Sales Value by Application (2021-2032)
  12. 5.3.3 Global Hepatitis A Vaccine Sales Value Share by Application (2021-2032)
6 Hepatitis A Vaccine Regional Sales and Value Analysis
  1. 6.1 Global Hepatitis A Vaccine Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Hepatitis A Vaccine Sales by Region (2021-2032)
  3. 6.2.1 Global Hepatitis A Vaccine Sales by Region: 2021-2026
  4. 6.2.2 Global Hepatitis A Vaccine Sales by Region (2027-2032)
  5. 6.3 Global Hepatitis A Vaccine Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Hepatitis A Vaccine Sales Value by Region (2021-2032)
  7. 6.4.1 Global Hepatitis A Vaccine Sales Value by Region: 2021-2026
  8. 6.4.2 Global Hepatitis A Vaccine Sales Value by Region (2027-2032)
  9. 6.5 Global Hepatitis A Vaccine Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Hepatitis A Vaccine Sales Value (2021-2032)
  12. 6.6.2 North America Hepatitis A Vaccine Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Hepatitis A Vaccine Sales Value (2021-2032)
  15. 6.7.2 Europe Hepatitis A Vaccine Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Hepatitis A Vaccine Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Hepatitis A Vaccine Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Hepatitis A Vaccine Sales Value (2021-2032)
  21. 6.9.2 South America Hepatitis A Vaccine Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Hepatitis A Vaccine Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Hepatitis A Vaccine Sales Value Share by Country, 2025 VS 2032
7 Hepatitis A Vaccine Country-level Sales and Value Analysis
  1. 7.1 Global Hepatitis A Vaccine Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Hepatitis A Vaccine Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Hepatitis A Vaccine Sales by Country (2021-2032)
  4. 7.3.1 Global Hepatitis A Vaccine Sales by Country (2021-2026)
  5. 7.3.2 Global Hepatitis A Vaccine Sales by Country (2027-2032)
  6. 7.4 Global Hepatitis A Vaccine Sales Value by Country (2021-2032)
  7. 7.4.1 Global Hepatitis A Vaccine Sales Value by Country (2021-2026)
  8. 7.4.2 Global Hepatitis A Vaccine Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Hepatitis A Vaccine Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Hepatitis A Vaccine Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Hepatitis A Vaccine Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 GSK
  2. 8.1.1 GSK Company Information
  3. 8.1.2 GSK Business Overview
  4. 8.1.3 GSK Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 GSK Hepatitis A Vaccine Product Portfolio
  6. 8.1.5 GSK Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Merck Hepatitis A Vaccine Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Hepatitis A Vaccine Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Sinovac
  20. 8.4.1 Sinovac Company Information
  21. 8.4.2 Sinovac Business Overview
  22. 8.4.3 Sinovac Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Sinovac Hepatitis A Vaccine Product Portfolio
  24. 8.4.5 Sinovac Recent Developments
  25. 8.5 Zhejiang Pukang
  26. 8.5.1 Zhejiang Pukang Company Information
  27. 8.5.2 Zhejiang Pukang Business Overview
  28. 8.5.3 Zhejiang Pukang Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Zhejiang Pukang Hepatitis A Vaccine Product Portfolio
  30. 8.5.5 Zhejiang Pukang Recent Developments
  31. 8.6 Changchun Institute of Biological
  32. 8.6.1 Changchun Institute of Biological Company Information
  33. 8.6.2 Changchun Institute of Biological Business Overview
  34. 8.6.3 Changchun Institute of Biological Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Changchun Institute of Biological Hepatitis A Vaccine Product Portfolio
  36. 8.6.5 Changchun Institute of Biological Recent Developments
  37. 8.7 KM Biologics
  38. 8.7.1 KM Biologics Company Information
  39. 8.7.2 KM Biologics Business Overview
  40. 8.7.3 KM Biologics Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 KM Biologics Hepatitis A Vaccine Product Portfolio
  42. 8.7.5 KM Biologics Recent Developments
  43. 8.8 IMBCA
  44. 8.8.1 IMBCA Company Information
  45. 8.8.2 IMBCA Business Overview
  46. 8.8.3 IMBCA Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 IMBCA Hepatitis A Vaccine Product Portfolio
  48. 8.8.5 IMBCA Recent Developments
  49. 8.9 ChangSheng
  50. 8.9.1 ChangSheng Company Information
  51. 8.9.2 ChangSheng Business Overview
  52. 8.9.3 ChangSheng Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 ChangSheng Hepatitis A Vaccine Product Portfolio
  54. 8.9.5 ChangSheng Recent Developments
  55. 8.10 Convac
  56. 8.10.1 Convac Company Information
  57. 8.10.2 Convac Business Overview
  58. 8.10.3 Convac Hepatitis A Vaccine Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Convac Hepatitis A Vaccine Product Portfolio
  60. 8.10.5 Convac Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Hepatitis A Vaccine Value Chain Analysis
  2. 9.1.1 Hepatitis A Vaccine Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Hepatitis A Vaccine Sales Mode & Process
  6. 9.2 Hepatitis A Vaccine Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Hepatitis A Vaccine Distributors
  9. 9.2.3 Hepatitis A Vaccine Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst